SEATTLE, Oct. 24, 2018 /PRNewswire/ — LumiThera Inc., a commercial-stage medical device company focused on developing photobiomodulation (PBM) therapies for ocular disorders and disease, announced a distribution agreement with Optos Plc, a division of Nikon, Inc., Japan to exclusively distribute the Valeda™ Light Delivery System for the treatment of dry age-related macular degeneration (AMD) in… Continue reading →

SEATTLE, Oct. 19, 2018 /PRNewswire/ — LumiThera® Inc., a commercial-stage medical device company focused on developing photobiomodulation (PBM) therapies for ocular disorders and disease, today announced that it will present at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology (OIS@AAO) meeting on October 25, 2018, in Chicago, IL. OIS unites industry, entrepreneurial and… Continue reading →

SEATTLE, Sept 14, 2018 /PRNewswire/ — LumiThera® Inc., a commercial-stage medical device company focused on developing photobiomodulation (PBM) therapies for ocular disorders and diseases, announced that it will participate in the combined exhibition of the 18th EURETINA Annual Meeting and the 36th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), held in… Continue reading →

SEATTLE, June 22, 2018 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company focused on developing non-invasive Photobiomodulation (PBM) therapies for ocular disorders and disease, announced CE Mark Certification for the European Union (EU) for the treatment of dry age-related macular degeneration (AMD) utilizing its LT-300 Light Delivery System. The “CE” mark is the… Continue reading →

SEATTLE, May 1, 2018 /PRNewswire/ — LumiThera Inc., a clinical stage medical device company focused on developing non-invasive Photobiomodulation (PBM) therapies for ocular disorders and disease, presented topline final results from the LIGHTSITE I clinical trial for the treatment of dry age-related macular degeneration (AMD) utilizing its LT-300 Light Delivery System. The LIGHTSITE I data… Continue reading →

SEATTLE, March 13, 2018 /PRNewswire/ — LumiThera Inc., a clinical stage medical device company focused on developing non-invasive photobiomodulation (PBM) therapies for ocular disorders and disease, today announces that Clark E. Tedford, Ph.D., Chief Executive Officer, is scheduled to present on Saturday, March 17, 2018 at 9:30 a.m. China Standard Time, at the 2018 Inaugural… Continue reading →

SEATTLE, Feb. 5, 2018 /PRNewswire/ — LumiThera, a clinical stage medical device company focused on developing photobiomodulation (PBM) therapies for ocular disorders and disease, today announced that it will participate in the 7th Annual Glaucoma 360 New Horizons Forum being held on Friday, February 9, 2018 at The Palace Hotel, in San Francisco. This meeting… Continue reading →

SEATTLE, Jan. 4, 2018 /PRNewswire/ — LumiThera a clinical stage medical device company focused on developing non-invasive photobiomodulation (PBM) therapies for ocular disorders and disease, today announced that it will present at the Digital Medicine and MedTech ShowcaseTM 2018, to be held January 8-10 during the most important week in healthcare at the Parc 55… Continue reading →

SEATTLE, November 7, 2017 /PRNewswire/ — LumiThera Inc., a clinical stage medical device company focused on developing non-invasive photobiomodulation (PBM) therapies for ocular disorders and disease, today announced topline interim results from the LIGHTSITE I trial for treatment of dry age-related macular degeneration (AMD) trial utilizing its LT-300 device. The 30-subject pilot study funded from… Continue reading →